The largest database of trusted experimental protocols

Mlck inhibitor

Manufactured by Merck Group

MLCK inhibitor is a laboratory reagent used to inhibit the activity of myosin light chain kinase (MLCK), an enzyme involved in the regulation of cellular contractility. This inhibitor helps researchers study the role of MLCK in various cellular processes.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using mlck inhibitor

1

Platelet Functional Assay Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Healthy blood donors and patient donors had abstained from aspirin in the last two weeks, and consent was obtained according to GT IRB H15258. Blood was drawn by median venipuncture into acid-citrate-dextrose (ACD) solution 2. The sample was subsequently centrifuged at 150 G for 15 min, and the resulting platelet rich plasma was gel filtered into HEPES modified Tyrodes buffer as described previously 35 . Platelets were diluted to a final concentration of 4 × 106/mL in Tyrodes buffer to minimize potential paracrine signaling. This equated to an average distance between microdot pairs of 30–50 microns depending on the donor. In some experiments, platelets were incubated for 1 hour with vehicle (dimethyl sulfoxide, DMSO); ROCK inhibitor Y-27632 at 50 μm (Sigma Y0503), or MLCK inhibitor at 10 μm (Sigma I2764).
For bulk contraction studies, blood was drawn by median antecubital venipuncture into acid-citrate-dextrose (ACD) solution 2. The sample was centrifuged 150 G for 15 min and the resulting platelet rich plasma was collected, and centrifuged with an additional 10% ACD by volume at 900G for 5min. The supernatant, platelet poor plasma, was discarded and the platelets were resuspended into HEPES modified Tyrodes buffer.
+ Open protocol
+ Expand
2

Platelet Functional Assay Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Healthy blood donors and patient donors had abstained from aspirin in the last two weeks, and consent was obtained according to GT IRB H15258. Blood was drawn by median venipuncture into acid-citrate-dextrose (ACD) solution 2. The sample was subsequently centrifuged at 150 G for 15 min, and the resulting platelet rich plasma was gel filtered into HEPES modified Tyrodes buffer as described previously 35 . Platelets were diluted to a final concentration of 4 × 106/mL in Tyrodes buffer to minimize potential paracrine signaling. This equated to an average distance between microdot pairs of 30–50 microns depending on the donor. In some experiments, platelets were incubated for 1 hour with vehicle (dimethyl sulfoxide, DMSO); ROCK inhibitor Y-27632 at 50 μm (Sigma Y0503), or MLCK inhibitor at 10 μm (Sigma I2764).
For bulk contraction studies, blood was drawn by median antecubital venipuncture into acid-citrate-dextrose (ACD) solution 2. The sample was centrifuged 150 G for 15 min and the resulting platelet rich plasma was collected, and centrifuged with an additional 10% ACD by volume at 900G for 5min. The supernatant, platelet poor plasma, was discarded and the platelets were resuspended into HEPES modified Tyrodes buffer.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!